CHATSWORTH, Calif., July 22, 2010 (GLOBE NEWSWIRE) -- IRIS International, Inc. (Nasdaq:IRIS), will provide a live listen-only webcast of its financial analyst and investor breakfast meeting and presentation on Wednesday, July 28, 2010. The in-person breakfast meeting is scheduled to begin at 7:30 a.m. Pacific time, with the live webcast and presentation beginning thereafter at 8:00 a.m. PT. IRIS senior management, led by Chairman and CEO Cesar Garcia, will provide an overview and update of the Company's business. The analyst meeting is being held in conjunction with the American Association for Clinical Chemistry (AACC) 2010 Annual Meeting and Clinical Lab Expo in Anaheim, Calif.
| Date: | Wednesday, July 28, 2010 |
| Time: | 7:30 a.m. (PT) - Breakfast Served |
| 8:00 a.m. (PT) - Webcast and Presentation to begin |
To listen via live webcast, please go to the "Investors" section of the IRIS website at: http://proiris.com. (10 min. before webcast is scheduled to begin).
To participate in the listen-only teleconference, please dial (10 min. before conference is scheduled to begin):
| Domestic toll-free: | 1-877-870-9220 |
| International: | + 973-638-3437 |
The conference call audio cast will be archived and available for replay in the Investors section of the Company's website at http://www.proiris.com for approximately 30 days.
Attendance at the 7:30 a.m. breakfast meeting in Anaheim is limited to financial analysts and professional investors. Those interested in attending the invitation only meeting, are asked to contact Ron Stabiner at 212-888-4848, or email: rstabiner@thewallstreetgroup.com. Immediately following the presentation, IRIS will conduct a tour and product demonstration at its booth no. 3035 on the floor of the AACC Clinical Lab Expo at the Anaheim Convention Center.
About IRIS International, Inc.
IRIS International is a leading global in vitro diagnostics company focused on products that analyze particles and living cell forms and structures, or morphology of a variety of body fluids. The Company's products leverage its strengths in flow imaging technology, particle recognition and automation to bring efficiency to hospital and commercial laboratories. The initial applications for its technology have been in the urinalysis market and the Company is the leading worldwide provider of automated urine microscopy and chemistry systems, with an installed base of more than 2,700 systems in more than 50 countries. The Company is expanding its core imaging and morphology expertise into related markets and is developing applications in hematology and urinary tract infections. In addition, the Company is developing molecular diagnostic tests based on its Nucleic Acid Detection Immunoassay, or NADiA®, platform, with applications in oncology and infectious disease. For more information visit www.proiris.com.